Navigation Links
Key Trigger Of Opioid Withdrawal Symptoms Found

Researchers have discovered an important chemical in the brain's neuronal machinery that triggers some of the withdrawal symptoms of opioid drugs like morphine and heroin.

They believe that drugs to inhibit the chemical--called a transporter--could relieve some of the early physical symptoms of withdrawal, such as teeth-chattering, uncontrolled shaking, and jumpiness. Such drugs could become part of the arsenal of medicines and behavioral techniques aimed at helping addicts kick their habits.


To zero in on the machinery underlying withdrawal symptoms, researchers led by Elena Bagley and Macdonald Christie of the Pain Management Research Institute at Royal North Shore Hospital (a division of the University of Sydney) performed biochemical studies on brain slices from mice that had been treated with morphine. Their objective was to understand what happens to a particular region of the midbrain--called the periaqueductal gray (PAG)--known to be involved in such withdrawal symptoms. Opiate addiction inhibits neuron activity in this region, which alters the neuronal machinery to compensate for this inhibition. Upon opiate withdrawal, the neurons rebound, becoming hyperactive.

The scientists' analysis revealed that a transporter molecule for the neurotransmitter GABA was responsible for the electrical abnormalities that produce a hyperexcitability in the neurons. Neurotransmitters are the molecular ammunition that one neuron fires at its neighbor to trigger a nerve impulse in the neighbor. Propagation of such nerve impulses through the networks of neurons in the brain is the basis of all neural activity. Transporter molecules are the proteins that retrieve neurotransmitter molecules from the spaces between neurons after they trigger nerve impulse, to reload the neuron for its next signaling burst.

Bagley and her colleagues also discovered that a molecular switch called protein kinase A was part of the triggering machinery involved in activating the abnormal GABA transporter activity.

Importantly, the researchers found that drugs that inhibit either the GABA transporter activity or protein kinase A eliminate the hyperexcitability of the PAG neurons in the mouse brain slices.

The researchers cited other studies showing that treatment with opioids also altered levels of the transporter for the neurotransmitter glutamate, "suggesting that neurotransmitter transporters may prove to be useful targets for management of opioid dependence," they wrote. The researchers also wrote that, since GABA is a neurotransmitter that inhibits nerve impulses, drugs to inhibit the GABA transporter "could produce their therapeutic effect through altering extracellular GABA concentrations as well as directly altering the excitability of GABAergic neurons."

###

Elena E. Bagley, Michelle B. Gerke, Christopher W. Vaughan, Stephen P. Hack, and MacDonald J. Christie: "GABA Transporter Currents Activated by Protein Kinase A Excite Midbrain Neurons during Opioid Withdrawal"

Publishing in Neuron, Volume 45, Number 3, February 3, 2005, pages 433?45. http://www.neuron.org


'"/>

Source:Cell Press


Related biology news :

1. Bacteria in Household Dust May Trigger Asthma Symptoms
2. Opiates Better Than Sedatives For Treating Newborns In Withdrawal
3. Menopause Symptoms May Come Back After Stopping Menopausal Hormone Therapy
4. Synthetic Protein Eases Arthritis Symptoms in Mice
5. Potential Drug Target For Treating Cocaine Abuse Found
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2019)... ... 17, 2019 , ... The possibility that ethnic differences exist ... for many years. These observed differences may be manifest in alterations in safety, ... residing in different geographic regions. This created the perceived necessity to fully and ...
(Date:1/10/2019)... , ... January 09, 2019 , ... Dr. Beanlands is ... Institute in Ottawa, Ontario, Canada. He is also Director of its National Cardiac ... Medicine, in the Department of Radiology, and in the Department of Cellular and Molecular ...
(Date:1/8/2019)... ... January 07, 2019 , ... ... solutions, is proud to welcome Thomas Kennedy as head of sales and business ... for PureWay. , Mr. Kennedy has previously worked for Johnson & Johnson Medical, ...
Breaking Biology News(10 mins):
(Date:1/8/2019)... , ... January 07, 2019 , ... ... its members into Noninvasix. This represents the second investment AngelMD has made into ... and morbidity, Noninvasix is developing a patient monitor to directly, accurately, and noninvasively ...
(Date:1/4/2019)... ... January 04, 2019 , ... Triangle Insights Group, a premier ... Ted will be joining the firm as a partner. , Ted has ... the pharmaceutical industry. At Triangle Insights, Ted will apply his deep expertise in ...
(Date:1/4/2019)... ... 03, 2019 , ... Calidi Biotherapeutics, Inc., a ... announced the founding of a scientific and medical advisory board (SMAB). The SMAB ... in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include Lisa ...
(Date:12/19/2018)... ... December 19, 2018 , ... RURO, Inc., a leading provider ... version 7.1. The new release enhances the latest version of Limfinity®, RURO’s software ... an end. , Validation protocols, and their execution, are critical for software systems ...
Breaking Biology Technology: